Self-Reported Adherence to Cancer Therapy: Development and Validation of the Domains of Subjective Extent of Nonadherence-Cancer Measure
JCO Oncology Practice · 2026
DOI: 10.1200/op-25-00477 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift JCO Oncology Practice, 2026. Verfasst von Yashasvini Sampathkumar und 20 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Neoplasms, Self Report, Medication Adherence, Drug Monitoring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Patients with cancer take different types of medications with varying schedules and settings. They are also sometimes instructed to stop medications due to toxicity. To measure self-reported nonadherence in this heterogeneous population, we modified and evaluated a measure originally developed to assess nonadherence to daily oral antihypertensives, the Domains of Subjective Extent of Nonadherence (DOSE-Nonadherence). METHODS The measure was refined in an iterative process incorporating feedback from patient investigators and participant interviews in English and Spanish. Branching logic was added for participant selection of medication administration setting: (1) only home, (2) only clinic, or (3) partly home/partly clinic. Participants reported their adherence to medications taken over a setting-specific reference period (1 week for home, 1 month for clinic medications). Participants who missed medications then reported on reasons for nonadherence. Adherence was dichotomized for analysis (complete adherence v any nonadherence). For participants who received clinic-administered medications, concordance between chart-abstracted and self-reported adherence was evaluated. RESULTS Seventy-three participants completed the measure (68% English; 32% Spanish; 86% female; 44% age ≥60 years). The majority had breast cancer; 64% had metastatic disease. Twenty-six percent (15/58) of participants who received medication in clinic and 24% (11/46) of those who took medication at home reported nonadherence. Participants felt able to respond accurately to both reference periods and perceived all reasons for nonadherence to be relevant. Among participants who completed the final version of the measure for clinic-administered medication, 96% (26/27) accurately reported their adherence compared with chart-abstracted data. CONCLUSION Our results support the validity of the DOSE-Nonadherence-Cancer for assessing cancer treatment nonadherence. This measure can be used to assess nonadherence in patients with cancer receiving a broad array of systemic therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY.
- University of Utah School of Medicine, Salt Lake City, UT.
- William S. Middleton Memorial Veterans Hospital, Madison, WI.
- Mayo Clinic, Scottsdale, AZ.
- University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
- Alliance for Clinical Trials in Oncology, Boston, MA.
ORCID-Profile: Yashasvini Sampathkumar, Gina L Mazza, Lauren Rogak, Elizabeth D Kantor, Antonia V Bennett, Patricia A Spears, Stephanie B Wheeler, Bryce B Reeve, Ethan Basch, Francesca Gany, Victoria Blinder
Förderung
- NCI NIH HHS
Zitieren
APA
Sampathkumar, Y., Voils, C. I., Mazza, G. L., Rogak, L., Ginos, B. F., Kantor, E. D., Bennett, A. V., Los Santos, Y., Suarez, J., Lopez, C., Narang, B., González, J., Killoran, K., Spears, P. A., Wolf, A. P., Weiss, A., Wheeler, S. B., Reeve, B. B., Basch, E., …, & Blinder, V. (2026). Self-Reported Adherence to Cancer Therapy: Development and Validation of the Domains of Subjective Extent of Nonadherence-Cancer Measure. JCO Oncology Practice. https://doi.org/10.1200/op-25-00477
Vancouver
Sampathkumar Y, Voils CI, Mazza GL, Rogak L, Ginos BF, Kantor ED, et al. Self-Reported Adherence to Cancer Therapy: Development and Validation of the Domains of Subjective Extent of Nonadherence-Cancer Measure. JCO Oncology Practice. 2026. doi:10.1200/op-25-00477
BibTeX
@article{Sampathkumar2026,
author = {Sampathkumar, Yashasvini and Voils, Corrine I and Mazza, Gina L and Rogak, Lauren and Ginos, Brenda F and Kantor, Elizabeth D and Bennett, Antonia V and Los Santos, Yulianny De and Suarez, Jennifer and Lopez, Camila and Narang, Bharat and González, Javier and Killoran, Kathleen and Spears, Patricia A and Wolf, Anna P and Weiss, Anna and Wheeler, Stephanie B and Reeve, Bryce B and Basch, Ethan and Gany, Francesca and Blinder, Victoria},
title = {Self-Reported Adherence to Cancer Therapy: Development and Validation of the Domains of Subjective Extent of Nonadherence-Cancer Measure},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-25-00477}
}
EUVIMED